Study of Healthy Aging and Physical Function With Elamipretide
NCT07275424
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will utilize a daily dose of elamipetide for 4 weeks and will screen a sufficient number of subjects for 30 subjects to enroll in the study. The planned duration of the study includes baseline measurement, followed by 4 weeks intervention period, a midpoint (2week ±3days) check-in phone interview, and post intervention visits that mirror the baseline visits. After the last injection, subjects will enter the 2-week follow-up period, concluded by the end-of-study contact.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Aging, Healthy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 65 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- David Marcinek
- Last updated on ClinicalTrials.gov
- December 10, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Washington · 1
- University of Washington · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.